UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 2129, 2026

Kiniksa Pharmaceuticals International, plc

(Exact name of Registrant as Specified in Its Charter)


England and Wales	001-730430	98-1795578
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

Kiniksa Pharmaceuticals International, plc

105 Piccadilly, Second Floor

London, W1J 7NJ

England, United Kingdom (781) 431-9100

(781) 431-9100

(Address, zip code and telephone number, including area code of principal executive offices)

Kiniksa Pharmaceuticals Corp.

100 Hayden Avenue

Lexington, MA, 02421

(781) 431-9100

(Address, zip code and telephone number, including area code of agent for service)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares $0.000273235 nominal value		KNSA		The Nasdaq Stock Market LLC
				(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 15.0107 ~~Entry~~Submission ~~into~~of Matters to a ~~Material~~Vote ~~Definitive~~of ~~Agreement~~Security Holders.

On May 29, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) at which a quorum was present. Holders of the Company’s Class A ordinary shares (“Class A Shares”) and Class B ordinary shares (“Class B Shares”) as of the close of business on April 6, 2026 (the “Record Date”) were entitled to notice of and to vote at the Annual Meeting. Each Class A Share was entitled to one vote per share and each Class B Share was entitled to ten votes per share.

OnThe ~~May~~following ~~21,~~are ~~2026,~~the ~~Kiniksa~~voting ~~Pharmaceuticals~~results ~~International,~~for ~~plc (~~the ~~“Company”)~~proposals ~~entered~~considered ~~into~~and avoted ~~deed~~upon ofat ~~waiver (~~the ~~“Deed”)~~Annual ~~with Baker Bros. Advisors LP~~Meeting, onall ~~behalf~~ of ~~each~~which ofwere ~~Baker~~described ~~Brothers~~in ~~Life~~the ~~Sciences,~~Company’s ~~L.P.~~definitive ~~and~~proxy ~~667,~~statement ~~L.P.~~filed ~~(the~~with ~~“Shareholders”), pursuant to which~~ the ~~Shareholders~~Securities ~~waived~~and ~~their~~Exchange ~~rights~~Commission toon ~~convert~~April ~~any of their Class A1 or Class B1 ordinary shares into Class A or Class B ordinary shares (“Conversion Rights”) if~~6, ~~immediately~~2026. ~~prior~~Each toproposal orbelow ~~following~~was ~~such~~duly ~~conversion,~~passed ~~the~~by ~~Shareholders would beneficially own more than 49.9% of~~ the Company’s ~~outstanding~~shareholders ~~voting~~at ~~rights.~~the Annual Meeting.

Proposal 1 - The ~~Deed~~re-election ~~may~~of ~~only~~Stephen beR. ~~amended~~Biggar, ~~waived~~G. orBradley ~~terminated~~Cole ~~upon~~and aBarry ~~vote~~D. ofQuart atas ~~least~~Class ~~75%~~II ofDirectors ~~the~~to ~~total~~serve ~~number~~on of the ~~Company’s~~Board ~~outstanding~~of ~~ordinary~~Directors ~~shares;~~until ~~provided,~~the ~~however~~2029 ~~that~~Annual noMeeting ~~vote~~of ~~shall~~Shareholders, beand ~~necessary~~until ~~for~~their ~~any~~respective ~~amendment~~successors ~~that~~have ~~(a)~~been ~~adds~~appointed ~~additional~~or ~~shareholders~~until totheir ~~the~~earlier ~~Deed~~resignation or ~~(b)~~vacation ~~adds~~of ~~additional restrictions to the Shareholders’ Conversion Rights~~office.

The foregoing description of the Deed is qualified in its entirety by reference to the Deed, a copy of which is filed hereto as Exhibit 10.1.


Nominee	Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
Stephen R. Biggar	37,474,114	11,999,916	13,825	4,425,771
G. Bradley Cole	48,299,818	1,174,991	13,046	4,425,771
Barry D. Quart	48,061,571	1,413,338	12,946	4,425,771

~~Item~~Proposal ~~9.01.~~2 - ~~Financial~~To ~~Statements~~approve ~~and~~the ~~Exhibits~~appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s UK statutory auditors until the close of the Company’s next Annual Meeting.

(d) Exhibits


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
53,857,053	48,432	8,141	0


ExhibitNo.		Description

10.1		Deed of Waiver, dated as of May 21, 2026, by and among the Company and Baker Bros. Advisors LP

104		Cover Page Interactive Data File (embedded within the inline XBRL document)

Proposal 3 - To ratify the appointment of PwC as the Company’s US independent registered public accounting firm for the fiscal year ending December 31, 2026.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
53,857,126	48,355	8,145	0

Proposal 4 - To authorize the Company’s board of directors, through its audit committee, to determine PwC’s remuneration in its capacity as the Company’s UK statutory auditors until the close of its next Annual Meeting of Shareholders.

~~SIGNATURES~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
53,890,585	12,498	10,543	0

	KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC

Date: May 26, 2026	By:	/s/ Douglas Barry
		Douglas Barry
		Senior Vice President, Chief Legal Officer and Secretary

Proposal 5 - To receive the Company’s UK statutory annual account and report for the period ended December 31, 2025.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
53,611,179	2,032	300,415	0

Proposal 6 - To approve, on an advisory non-binding basis, the Company’s UK Statutory Directors’ Annual Remuneration Report for the period ended December 31, 2025.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
48,353,142	1,104,811	29,902	4,425,771

Proposal 7 - To approve the Company’s UK Statutory Directors’ Remuneration Policy.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
48,633,937	824,799	29,119	4,425,771

Proposal 8 - To approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
48,145,082	1,334,278	8,495	4,425,771

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC

Date: May 29, 2026	By:	/s/ Douglas Barry
		Douglas Barry
		Senior Vice President, Chief Legal Officer

Filing Compare · Kiniksa Pharmaceuticals International, plc